PALI
Palisade Bio·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 1
Bearish signal 1
Ample Liquidity
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About PALI
Palisade Bio, Inc.
A clinical-stage biopharmaceutical company focused on developing oral therapies for serious diseases associated with disruption of the mucosal barrier that protects the gastrointestinal tract
1902 Wright Place, Suite 200, Carlsbad, California1
--
Palisade Bio, Inc., founded in 1997, is a biopharmaceutical company dedicated to providing treatment options for central nervous system diseases using its unique human neural stem cell technology. The company will commercialize this technology to make it a tool for discovering next-generation small molecule drugs and create a biological cell therapy to treat central nervous system diseases. The company currently has laboratories and offices in Rockville, Maryland, as well as experimental equipment in San Diego and China. Neuralstem, Inc., develops and maintains a series of patents and patent applications that form the proprietary basis of its research and development efforts. The Company owns or exclusively licenses thirty (30) US and foreign granted patents and forty-two (42) US and foreign patent applications in the field of regenerative medicine, covering its stem cell technology and its small molecule compounds.
Company Financials
EPS
PALI has released its 2025 Q3 earnings. EPS was reported at -0.38, versus the expected -0.27, missing expectations. The chart below visualizes how PALI has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
